American Capital Advisory’s Neurocrine Biosciences NBIX Stock Holding History

American Capital Advisory’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.01K	Buy	+6	New	+$890	﹤0.01%	785
2026 Q1	–	Sell	-1	Closed	-$142	–	1186
2025 Q4	$142	Hold	1	–	–	﹤0.01%	957
2025 Q3	$141	Hold	1	–	–	﹤0.01%	920
2025 Q2	$126	Sell	1 -1	-50%	-$115	﹤0.01%	829
2025 Q1	$222	Buy	+2	New	+$253	﹤0.01%	716

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

American Capital Advisory's NBIX Position: Q2 2026 in Review

American Capital Advisory opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 6 shares worth $1.01K. The stake represents ﹤0.01% of the portfolio and ranks #785 among its holdings. This is a return to the name: American Capital Advisory previously reported a position in NBIX as recently as Q4 2025.

American Capital Advisory first reported a position in NBIX in Q1 2025 and has held it in 5 quarters since. 778 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

American Capital Advisory held 6 shares of Neurocrine Biosciences worth $1.01K as of Q2 2026.
Neurocrine Biosciences was a new American Capital Advisory position in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of American Capital Advisory's portfolio in Q2 2026, its #785 holding.
American Capital Advisory first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 5 quarters since.
778 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.